PHVS

Pharvaris N.V. (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Leiden, the Netherlands. The company went public in February 2021 and operates across the Netherlands, Switzerland, and the United States. Pharvaris focuses exclusively on developing innovative therapies for hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling episodes. The company is currently advancing three drug candidates through various phases of clinical trials, with its lead compound having reached Phase II development.